March 10, 2022 4:46pm

As I stated this a.m., “time to take some chips off the table. I’m reacting, not waiting for the swing downward, count them alternately after every big bounce.”

The Biostage (BSTG) Chronicles: shows how the “pimp/pump and promote” works on Thursday -$0.63 with 488 shares traded – just a “zombie” equity for non-U.S. Chinese investors

Pre-open indications: 12 Hits and 0 Miss

What I provide is an intelligence daily. RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

The Bottom Line says it all succinctly … just the facts

Who else is tracking a broad grouping of cell and gene therapy equities – can you afford to not read the facts supported by real numbers?

If I have learned one thing as a former research analyst, venture and public fund investor now a journalist; it is that your life and your bank account are largely tied to your knowledge of price movements and questioning pricing targets.

 

The Dow closed DOWN -113.23 points (-0.34%); the S&P closed DOWN -18.48 points (-0.43%) while the Nasdaq closed DOWN -125.58 points (-0.95%)

 

Henry’omics:

Indexes fell Thursday after failed peace talks between Ukraine and Russia ministers ended with little progress on matters including a cease-fire or a safe passage for civilians trying to flee the besieged city of Mariupol.

Inflation is getting worst …

The consumer price index, a key inflation gauge, showed a wide-ranging basket of goods and services increased 7.9% in February, a fresh 40-year high. This was a touch higher than the estimate of 7.8% for the year, according to economists.

On a month-over-month basis, the CPI gain was 0.8%, compared to the estimate of 0.7% for the month.

 

This a.m.’s post, RegMed Investors’ (RMi) pre-open: “time to take some chips off the table. I’m reacting, not waiting for the swing downward, count them alternately after every big bounce” … https://www.regmedinvestors.com/articles/12335

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened …

  • Thursday opened negative at 3 up/35 downs, stayed negative at the mid-day at 9/29, ending with a negative close of 6/26;

 

Pre-open Indications: 12 Hits < Biostage (BSTG -$0.63), Profit - Agenus (AGEN -$0.15), Beam Therapeutics (BEAM +$0.75), Chinook Therapeutics (KDNY +$0.21), CRISPR Therapeutics (CRSP +$0.05), Intellia Therapeutics (NTLA -$0.01), Pharmaceuticals (IONS -$0.33), Voyager Therapeutics (VYGR -$0.09), Regenxbio (RGNX +$0.39), Sage Therapeutics (FATE -$0.73), Sangamo Therapeutics (SGMO -$0.75), Ultragenyx (RARE -$0.16)> 0 Miss

 

RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628  …

 

The Biostage (BSTG) Chronicles: shows how the “pimp/pump and promote” works on Thursday -$0.63 with 488 shares traded after Wednesday -$0.26 with 1,225 shares traded, Tuesday flat with 1,130 shares traded, Monday’s close +$0.29 with 399 shares traded, Friday closing down -$0.44 with 1,303 shares traded after last Thursday as 487 shares traded moving the share price +$0.25

  • WHO is BUYING these shares of a company with a 3-year-old IND, NO clinical trial initiation, a terminal death lawsuit overhang and a dwindling cash position?
  • By use of the pump/promote process; is BSTG preparing to register the outstanding private placement (PP) shares for a reverse to initiate an offering
  • BSTG is NOT going ANYWHERE without a cash infusion.

 

Key Metrics:

  • Thursday - Sector volume was LOW with 1 of the 12-upside having higher than the 3-month average volume with LOW volume of 2 of 26-downside having higher than the 3-month average volume;

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Thursday, the IBB closed down -1.01% and XBI closed down -0.52%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Thursday was down -2.22 points or -6.84% at 30.23

 

Jumping with share pricing momentum (12 of 12):

  • ReNeuron (RENE.L +$2.00 after Wednesday’s -$0.75, Tuesday’s -$0.25 and Monday’s -$1.00),
  • Beam Therapeutics (BEAM +$0.61 after Wednesday’s +$2.64 and Tuesday’s -$0.34),
  • Regenxbio (RGNX +$0.41 after Wednesday’s -$0.08),
  • Chinook Therapeutics (KDNY +$0.21),
  • Bellicum Pharmaceuticals (BLCM +$0.07),
  • Fate Therapeutics (FATE +$0.07 after Wednesday’s +$2.64, Tuesday’s +$0.91 and Monday’s -$0.61)
  • Mesoblast (MESO +$0.06 after Wednesday’s +$0.82),
  • Cellectis SA (CLLS +$0.06),
  • Avrobio (AVRO) +$0.03),
  • CRISPR Therapeutics (CRSP +$0.01 after Wednesday’s +$2.07, Tuesday’s +$5.15 and Monday’s +$2.01),
  • Applied Genetic Technologies (AGTC +$0.01),
  • Caladrius Biosciences (CLBS +$0.0078),

Hammered in today’s market (10 of 26):

  • Alnylam Pharmaceuticals (ALNY -$1.67),
  • Vericel (VCEL -$1.41 after Wednesday’s +$1.23, Tuesday’s -$1.11 and Monday’s -$1.76),
  • Biostage (BSTG -$0.63 after Wednesday’s -$0.26),
  • Sage Therapeutics (SAGE -$0.62),
  • Global Blood Therapeutics (GBT -$0.610,
  • BioLife Solutions (BLFS -$0.45 after Wednesday’s +$1.12, Tuesday’s -$0.36 and Monday’s -$0.36),),
  • Editas Medicine (EDIT -$0.40),
  • bluebird bio (BLUE -$0.36),
  • AxoGen (AXGN -$0.33),
  • Caribou Therapeutics (CRBU -$0.24),

 

March, Q1/2022:

  • Thursday closed negative with 12 incliners and 36 decliners

 

The BOTTOM LINE: Uncertainties surround the cell and gene therapy sector …

The sector was mostly lower, as algorithms stripped most equities of any upside (the downfall range was -7.23% and -0.38%.

bluebird bio (BLUE), Biostage (BSTG) and Precigen (PGEN) led the losers while the winners – ReNeuron (RENE.L.) Bellicum Pharmaceuticals (BLCM) and Cellectis SA (CLLS)

I don't think we've seen the bottom yet. And I'd like to be more optimistic, but the reason I say this is the algorithms are always lurking for profiting.

The cell and gene therapy sector’s volume remain LOW.

Remember the adage, “It takes two to make a market"; that’s sellers and buyers.

I stick to my view of anticipating the risks – as my careers focus has been “warning analysis”; risk to growth now takes center stage for how long separation of sentiment lasts and how deep the oversold dive.

Q4 and end-of-year earnings are “gamy” than even I thought.

Earnings’ reporting coming:

·         Athersys (ATHX), Tuesday, 3/15

·         Cellectis SA (CLLS) Thursday, 3/22

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.